低剂量和高剂量持续输注阿糖胞苷的药理学研究。 - Suppr | 超能文献

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.

作者信息

Kufe D W, Spriggs D R, Griffin J D

出版信息

Semin Oncol. 1987 Jun;14(2 Suppl 1):149-58.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.低剂量和高剂量持续输注阿糖胞苷的药理学研究。

Semin Oncol. 1987 Jun;14(2 Suppl 1):149-58.

2

Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.

Semin Oncol. 1987 Jun;14(2 Suppl 1):58-63.

3

Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.

Leukemia. 1990 Nov;4(11):790-6.

4

Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.用中剂量阿糖胞苷（ara-C）治疗复发或难治性急性髓系白血病（AML）：证实阿糖胞苷三磷酸形成在介导对阿糖胞苷反应中的重要性。

Leuk Lymphoma. 1993;10 Suppl:115-21. doi: 10.3109/10428199309149123.

5

Biochemical and cellular pharmacology of cytosine arabinoside.

Semin Oncol. 1985 Jun;12(2 Suppl 3):34-48.

6

Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.

Clin Sci (Lond). 1981 Feb;60(2):191-8. doi: 10.1042/cs0600191.

7

Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.在MD安德森医院开展的高剂量阿糖胞苷临床研究的进展

Semin Oncol. 1985 Jun;12(2 Suppl 3):98-104.

8

Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.基于白血病细胞中代谢物水平计算阿糖胞苷（ara-C）的个体给药方案。

Ther Drug Monit. 1994 Aug;16(4):375-9. doi: 10.1097/00007691-199408000-00007.

9

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.高剂量1-β-D-阿拉伯呋喃糖基胞嘧啶治疗期间白血病细胞中1-β-D-阿拉伯呋喃糖基胞嘧啶5'-三磷酸积累的饱和度

Cancer Res. 1987 Jun 1;47(11):3005-11.

10

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.大剂量阿糖胞苷治疗期间阿糖胞苷三磷酸（ara-CTP）蓄积的饱和现象：中等剂量阿糖胞苷的药理学依据。

Semin Oncol. 1987 Jun;14(2 Suppl 1):159-66.

引用本文的文献

1

In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.原始细胞对白细胞介素-3、粒细胞-巨噬细胞集落刺激因子和粒细胞集落刺激因子的体外反应在个体急性髓系白血病患者中存在差异：刺激白血病克隆形成细胞的因素也会增强阿糖胞苷的细胞毒性。

Ann Hematol. 1994 May;68(5):225-32. doi: 10.1007/BF01737421.

2

In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.

Cancer Chemother Pharmacol. 1989;23(2):87-94. doi: 10.1007/BF00273523.

3

Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.阿糖胞苷在急性髓系白血病治疗中的作用：大剂量方案的作用及地位

Ann Hematol. 1991 Apr;62(4):119-28. doi: 10.1007/BF01702925.